Earlier this month (July 10, 2026), the German government voted through a sweeping set of provisions set to significantly impact medical cannabis patients who have their prescriptions covered by their statutory health insurance.
Cannabis Europa London returns on 26-27 May 2026, bringing together operators, investors, clinicians and policymakers from across the global cannabis industry for two days of main stage debate, exhibition, and networking.
Last week (April 27), the deadline for Greek industry stakeholders to have their say on a controversial new hemp ban expired.
In April 2025, the Italian government used emergency constitutional powers to bypass parliament and reclassify non-intoxicating hemp as a narcotic, regardless of THC content, following multiple failed attempts to decimate the industry.
The M&A scramble for Europe has continued at a fearsome pace over the last few weeks.
This morning, the latest in a now-weekly series of stories in the British mainstream press was published in The Times, for the second week in a row taking aim at the advertising practices of some of the UK’s largest clinics.
Scrutiny of the UK’s medical cannabis industry has rarely, if ever, been so acute since it was legalised in 2018.
More than 70 international speakers and over 1000 delegates set to convene on London next month for policy debates, high-level networking and the 2026 Business of Cannabis Awards Cannabis Europa, the leading B2B conference for the European cannabis industry, today announced the full programme for its 2026 London edition.
As the European medical cannabis market has developed, expanded and matured over the last half-decade, Portugal has played a critical role in the global supply chain, earning a reputation as the ‘doorway to Europe’.
